New hope for kidney cancer: targeted pill aims to stop tumor growth
NCT ID NCT03786796
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a daily pill called olaparib in 20 adults with advanced kidney cancer that has spread. To join, your cancer must have a specific gene change (like BAP-1 or BRCA) and you must have already tried at least one other treatment. The goal is to see if olaparib can shrink tumors or keep them stable for at least six months.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KIDNEY CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
RECRUITINGBaltimore, Maryland, 21228, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can we predict who needs extra therapy after kidney cancer surgery?
- Can a pill boost the immune system to fight Hard-to-Treat cancers?
- Can a Two-Drug combo outsmart advanced cancers?
- Can a rapid drug switch outsmart advanced kidney cancer?
- Can a new nucleotide analogue boost cancer treatment?
- Can a blast of radiation make immunotherapy work better against kidney cancer?